Fat distribution and metabolic changes in patients with HIV infection

AIDS

Volumn 13, Issue 18, 1999, Pages 2493-2505

  Safrin, Sharon ^a,b   Grunfeld, Carl ^a,c  

^a Department of Medicine ^*  (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Body composition; Fat redistribution; HIV infection; Hyperlipidemia; Insulin resistance; Lipoatrophy; Lipodystrophy; Lipohypertrophy

Indexed keywords

FAT; GLUCOSE; INSULIN; PROTEINASE INHIBITOR;

AGE; BODY COMPOSITION; BODY FAT; BODY WEIGHT; FEMALE; GENDER; GLUCOSE METABOLISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; INSULIN RESISTANCE; LIPID METABOLISM; LIPOATROPHY; LIPODYSTROPHY; MALE; PREVALENCE; PRIORITY JOURNAL; REVIEW; VIRUS LOAD;

BODY WEIGHT; FATS; GLUCOSE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; LIPID METABOLISM; LIPODYSTROPHY; SYNDROME;

EID: 0033396957     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199912240-00002     Document Type: Review

References (83)

1. 1. Lo JC, Mulligan K, Tai VW, Algren H, Schambelan M. Buffalo hump in men with HIV-1 infection. Lancet 1998, 351:867-870.
2. 2. Miller K, Daly P, Sentochnik D, et al. Pseudo-Cushing's syndrome in human immunodeficiency virus-infected patients. Clin Infect Dis 1998, 27:68-72.
3. 3. Roth V, Kravcik S, Angel J. Development of cervical fat pads following therapy with human immmunodeficiency virus type 1 protease inhibitors. Clin Infect Dis 1998, 27:65-67.
4. 4. Hengel R, Watts N, Lennox J. Benign symmetric lipomatosis associated with protease inhibitors [letter]. Lancet 1997, 350:1596.
5. 5. Wurtz R. Abnormal fat distribution and use of protease inhibitors. Lancet 1998, 351:1735-1736.
6. 6. Stricker R, Goldberg B, Martinez E. Fat accumulation and HIV-1 protease inhibitors. Lancet 1998, 352:1392-1392.
7. 7. Lo JC, Mulligan K, Tai VW, Algren H, Schambelan M. Body shape changes in HIV-infected patients. J Acquir Immune Def Syndr 1998, 19:307-308.
8. 8. Striker R. Conlin D, Marx M, Wiviott L. Localized adipose tissue hypertrophy in patients receiving human immunodeficiency virus protease inhibitors. Clin Infect Dis 1998, 27:218-220.
9. 9. Reboli AC, Marshall S. Changes in body habitus in HIV-infected patients treated with protease inhibitors. IDSA 36th Annual Meeting. Denver, November 1998 [abstract 476 Sa].
10. 10. Hengel RL, Geary JAM, Vuchetich MA, et al. Multiple symmetrical lipomatosis associated with protease inhibitor therapy. Fifth Conference on Retroviruses and Opportunistic Infections. Chicago, January 1998 [abstract 407].
11. 11. Dong K, Bausserman LL, Flynn MM, et al. Changes in body habits and serum lipid abnormalities in HIV-positive women on highly active antiretroviral therapy (HAART). J Acquir Immune Def Syndr Hum Retrovirol 1999, 21:107-113.
12. 12. Boix V, Reus S, Priego M, et al. Expanding the spectrum of protease inhibitors-induced lipodystrophy. 12th World AIDS Conference. Geneva, June 1998 [abstract 12398].
13. 13 Lui A, Karter D, Turrett G. Another case of breast hypertrophy in a patient treated with indinavir. Clin Infect Dis 1998, 26:1482.
14. 14. Mann M., Piazza-Hepp T, Koller E, Gibert C. Abnormal fat distribution in AIDS patients following protease inhibitor therapy: FDA summary. Fifth Conference on Retroviruses and Opportunistic Infections. Chicago, January 1998 [abstract 412].
15. 15. Sutinen J, Mathur-Wagh U. Changes in body shape during PI therapy in HIV+ women. 6th Conference on Retroviruses and Opportunistic Infections. Chicago, January 1999 [abstract 662].
16. 16. Gervasoni C, Ridolfo AL, Trifiro G, et al. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS 1999, 13:465-471.
17. 17. Miller K, Jones E, Yanovski J, Shankar R, Feuerstien I, Falloon J. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 1998, 351:871-875.
18. 18. Lipsky J. Abnormal fat accumulation in patients with HIV-1 infection. Lancet 1998, 351:847-848.
19. 19. Rosenberg HE, Mulder J, Sepkowitz KA, Giordano MF. 'Protease-paunch' in HIV+ persons receiving protease inhibitor therapy: incidence, risks and endocrinologic evaluation. Fifth Conference on Retroviruses and Opportunistic Infections. Chicago, January 1998 [abstract 408].
20. 20 Engelson ES, Kotler DP, Tan YX, et al. Fat distribution in HIV-infected patients reporting truncal enlargement quantified by whole-body magnetic resonance imaging. Am J Clin Nutr 1999, 69:1162-1169.
21. 21. Carr A, Samaras K, Burton S, Freund I, Chisholm DJ, Cooper DA. A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance due to HIV protease inhibitors. AIDS 1998, 12:F51-F58.
22. 22. Viraben R, Aquuilina C. Indinavir-associated lipodystrophy. AIDS 1998, 12:F37-F39.
23. 23. Shaw A, McLean K, Evans B. Disorders of fat distribution in HIV infection. Int J STD & AIDS 1998, 9:595-599.
24. 24. Bonnet E, Cuzin L, Sailler L, et al. Associated lipodystrophy metabolic disorders due to protease inhibitor containing regimens. 12th World AIDS Conference. Geneva, June 1998 [abstract 12299].
25. 25. Wong KH, Ho Ty, Chan CW, Lee SS. Indinavir-associated facial atrophy in HIV positive patients. 12th World AIDS Conference. Geneva, June 1998 [abstract 12391].
26. 26. Bonjoch A, Veny A, Johnston S, et al. Body composition measurements by anthropometry and bioelectrical impedance to evaluate redistribution of body fat in HIV-Positive patients on antiretroviral treatment. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, September 1998 [abstract 1-66].
27. 27. Veny A, Bonjoch J, Romeu M, et al. Cumulative risk for developing protease inhibitor-associated lipodystrophy (PI-AL) in HIV-infected patients. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, September 1998 [abstract 1-92].
28. 28. Carr A, Samaras K, Thorisdottir A, Kauffman GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999, 353:2093-2099.
29. 29. Gharakhanian, Salhi Y, Nguyen TH, et al. Frequency of lipodystrophy and factors associated with glucose/lipid abnormalities in a cohort of 650 patients treated by protease inhibitors. Sixth Conference on Retroviruses and Opportunistic Infections. Chicago, January 1999 [abstract 642].
30. 30. Kotler DP, Rosenbaum KB, Wang J, Pierson RN. Studies of body composition and fat distribution in HIV-infected and control subjects. J Acquir Immune Def Syndr Human Retrovirol 1999: 20:228-237.
31. 31. Saint-Marc T, Touraine, IL. Buffalo hump in HIV-1 infection. Lancet 1998, 352:319-320.
32. 32. Saint-Marc T, Poizot-Martin I, Partisani M, Fabre J, Touraine JL. A syndrome of lipodystrophy in patients receiving a stable nucleoside-analogue therapy. Sixth Conference on Retroviruses and Opportunistic Infections. Chicago, January 1999 [abstract 653].
33. 33. Madge S, Kinloch-DeLoes S, Tyrer M, Johnson MA. Lipodystrophy in patients naïve to protease inhibitors. AIDS 1999, 13:735-737.
34. 34. Walli R, Herfort O, Michl GM, et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS 1998, 12:F167-F173.
35. 35. Behrens GMN, Dejam A, Schmidt H, et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 1999, 13:F63-F70.
36. 36. Yanovski JA, Miller KD, Kino T, et al. Endocrine and metabolic evaluation of human immunodeficiency virus-infected patients with evidence of protease inhibitor-associated lipodystrophy. J Clin Endocrinol Metab 1999, 84:1925-1931.
37. 37. Caan B, Armstrong MA, Selby JV, et al. Changes in measurements of body fat distribution accompanying weight change. Int J Obes Relat Metab Disord 1994, 18:397-404.
38. 38. Seidell JC, Han TS, Feskens EJ, Lean ME. Narrow hips and broad waist circumferences independently contribute to increased risk of non-insulin-dependent diabetes mellitus. J Intern Med 1997, 242:401-406.
39. 39. Ross R, Rissanen J. Mobilization of visceral and subcutaneous adipose tissue in response to energy restriction and exercise. Am J Clin Nutr 1994, 60:695-703.
40. 40. Chowdhury B, Kvist H, Andersson B, Bjorntorp, P, Sjostrom L. CT-determined changes in adipose tissue distribution during a small weight reduction in obese males. Int J Obes Relat Metab Disord 1993, 17:685-91.
41. 41. Van der Kooy K, Leenen R, Seidell JC, Deurenberg P, Droop A, Bakker CJ. Waist-hip ratio is a poor predictor of changes in visceral fat. Am J Clin Nutr 1993, 57:327-333.
42. 42. Kissebah AH, Vydelingum N, Murray R, et al. Relation of body fat distribution to metabolic complications of obesity. J Clin Endocrinol Metab 1982,54:254-260.
43. 43. Lapidus L, Bengtsson C, Larsson B, Pennert K, Rybo E, Sjostrom L. Distribution of adipose tissue and risk of cardiovascular disease and death. I. 12-year follow-up of participants in the population study of women in Goethenburg, Sweden. BMJ 1984, 289:1257-1261.
44. 44. Larsson B, Svardsudd K, Welin L, Wilhelmsen L, Bjorntorp P, Tibblin G. Abdominal adipose tissue distribution, obesity and risk of cardiovascular disease and death: a 13-year follow-up of participants in the study of men born in 1913. BMJ 1984, 288:1401-1404.
45. 45. Despres JP, Marette A. Relation of components of insulin resistance syndrome to coronary disease risk. Curr Opin Lipidol 1994, 5:274-289.
46. 46. Bjorntorp P. Body fat distribution, insulin resistance and metabolic diseases. Nutrition 1997, 13:795-803.
47. 47. Bouchard C, Depres J-P, Mauriege P. Genetic and nongenetic determinants of regional fat distribution. Endocrinol Rev 1993, 14:72-93.
48. 48. Despres J-P, Prud'Homme D, Pouliot M-C, Tremblay A, Bouchard C. Estimation of deep abdominal adipose-tissue accumulation from simple anthropometric measurements in men. Am J Clin Nutr 1991, 54:471-477.
49. 49. Hill JO, Sidney S, Lewis CE, Tolan K, Scherzinger AL, Stamm ER. Racial differences in amounts of visceral adipose tissue in young adults: the CARDIA (Coronary Artery Risk Development in Young Adults) Study. Am J Clin Nutr 1999, 69:381-387.
50. 50. Sidney S, Lewis CE, Hill JO, et al. Association of total and central adiposity measures with fasting insulin in a biracial population of young adults with normal glucose tolerance: the CARDIA study. Obes Res 1999, 7:265-272.
51. 51. Han TS, McNeill G, Seidell JC, Lean ME. Predicting intra-abdominal fatness from anthropometric measures: the influence of stature. Int J Obes Relat Metab Disord 1997, 21:587-593.
52. 52. Van der Kooy, Leenen R, Seidell JC, Deurenberg P, Visser M. Abdominal diameters as indicators of visceral fat: comparison between magnetic resonance imaging and anthropometry. Br J Nutr 1993, 70:47-58.
53. 53. Van der Kooy K, Seidell JC. Techniques for the measurement of visceral fat: a practical guide. Int J Obes Relat Metab Disord 1993, 17: 187-196.
54. 54. Silva M, Skolnik P, Grobach S, et al. The effect of protease inhibitors on weight and body composition in HIV-infected patients. AIDS 1998, 12:1645-1651.
55. 55. Carbonnel F, Maslo C, Beaugerie L, et al. Effect of indinavir on HIV-related wasting. AIDS 1998, 12:1777-1784.
56. 56. Schwenk A, Beijenherz A, Kermer G, et al. Impact of protease inhibitor treatment on body composition and prevalence of malnutrition in HIV-positive outpatients. 12th World AIDS Conference. Geneva, June 1998 (abstract 32177).
57. 57. Grunfeld C, Feingold KR. Seminars in medicine of the Beth Israel Hospital, Boston. Metabolic disturbances and wasting in the acquired immunodeficiency syndrome. N Engl J Med 1992, 327:329-337.
58. 58. Grunfeld C, Kotler DP, Hamadeh R, Tierney A, Wang J, Pierson Jr RN. Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 1989, 86:27-31.
59. 59. Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992, 74:1045-1052.
60. 60. Hellerstein MK, Grunfeld C, Wu, K, et al. Increased de novo hepatic lipogenesis in human immunodeficiency virus-infected humans. J Clin Endocrinol Metab 1993, 76:559-565.
61. 61. Grunfeld C, Kotler DP, Shigenaga JK, et al. Circulating Interferon alpha levels and hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 1991, 90:154-162.
62. 62. Mildvan D, Machado SG, Wilets I, Grossberg SE. Endogenous Interferon and triglyceride concentrations to assess response to zidovudine in AIDS and advanced AIDS-related complex. Lancet 1992, 339.453-456.
63. 63. Stein TP, Nutinsky C, Condoluci D, Schluter MD, Leskiw MJ. Protein and energy substrate metabolism in AIDS patients. Metabolism 1990, 39:876-881.
64. 64. Hadigan C, Miller K, Corcoran C, Anderson E, Basgoz N, Grinspoon S. Fasting hyperinsulinemia and changes in regional body composition in human immunodeficiency virus-infected women. J Clin Endocrinol Metab 1999, 84:1932-1937
65. 65. Hommes MJT, Romijn JA, Endert E, Eeftinck-Schattenkerk JKM, Sauerwein HP. Basal fuel homeostasis in symptomatic human immunodeficiency virus infection. Clin Sci 1991, 80:359-365.
66. 66. Hommes MJT, Romijn JA, Endert E, Eeftinck-Schattenkerk JKM, Sauerwein HP. Insulin sensitivity and insulin clearance in human immunodeficiency virus-infected men. Metabolism 1991, 40:651-656.
67. 67. Mulligan K, Grunfeld C, Hellerstein MK, Neese RA, Schambelan M. Anabolic effects of recombinant human growth hormone in patients with wasting associated with human immunodeficiency virus infection. J Clin Endocrinol Metab 1993, 77:956-962.
68. 68. Heijligenberg R, Romijn JA, Hommes MJT, Endert E, Eeftinck-Schattenkerk JKM, Sauerwein HP. Non-insulin-mediated glucose uptake in human immunodeficiency virus-infected men. Clin Sci 1993, 84:209-216.
69. 69. Dube MP, Johnson DL, Currier JS, Ledom JM. Protease inhibitor-associated hyperglycaemia. Lancet 1997, 350:713-714.
70. 70. Eastone JA, Decker CF. New-onset diabetes mellitus associated with use of protease inhibitor. Ann Intern Med 1997, 127:948.
71. 71. Visnegarwara F, Krause KL, Musher DM. Severe diabetes associated with protease inhibitor therapy. Ann Intern Med 1997, 127:947.
72. 72. Caldwell R, Rothstein A, Allmon C, Montoya JG, Zolopa A. Evaluation of protease inhibitor-associated hyperglycemia in a university-based HIV clinic. 12th World AIDS Conference. Geneva, June 1998 [abstract 12395].
73. 73. Dong BJ, Gruta CI, Legg JJ. Diabetes and use of protease inhibitors. 12th World AIDS Conference. Geneva, June 1998 [abstract 12327].
74. 74. Tsiodras S, Mantzoros C, Hammer SM, Samore M. Effects of protease inhibitor use on hyperglycemia and hyperlipidemia: a five year analysis. Sixth Conference on Retroviruses and Opportunistic Infections. Chicago, January 1999 [abstract 643].
75. 75. Chang E, Deleo M, Liu YT, et al. The effects of antiretroviral protease inhibitors (Pls) on serum lipids and glucose in HIV-infected patients. 12th World AIDS Conference. Geneva, June 1998 [abstract 12381].
76. 76. Diaz L, Wiewora R. Diabetes, HIV infection and use of protease inhibitors 12th World AIDS Conference. Geneva, June 1998 [abstract 60148].
77. 77. Lee D, Matthews WC. Prevalence and risk factors for hyperglycemia, dyslipidemia, and coronary disease among HIV-infected patients on initial protease inhibitor therapy. Sixth Conference on Retroviruses and Opportunistic Infections. Chicago, January 1999 [abstract 644].
78. 78. Falutz J. Lipid abnormalities and body composition alterations in progressive stages of the HIV/HAART associated lipodystrophy (HAL) syndrome. Sixth Conference on Retroviruses and Opportunistic Infections. Chicago, January 1999 [abstract 646].
79. 79. Bausserman L, Flynn M, Dickenson R, Mileno M, Carpenter C. Relationship between body fat distribution, lipoprotein levels and fasting insulin in HIV+ women treated with protease inhibitors (PI). Sixth Conference on Retroviruses and Opportunistic Infections. Chicago, January 1999 [abstract 659].
80. 80. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance, Lancet 1998, 351: 1881-3.
81. 81. Juette A, Salzberger B, Franzen C, Roemer K, Diehl V, Faetkenheuer G. Increased morbidity from severe coronary heart disease in HIV-patients receiving protease inhibitors. Sixth Conference on Retroviruses and Opportunistic Infections. Chicago, January 1999 [abstract 656].
82. 82. Klein D, Sidney S, Hurley L, Iribaren C. Do protease inhibitors increase the risk for coronary heart disease among HIV positive patients? Sixth Conference on Retroviruses and Opportunistic Infections. Chicago, January 1999 [abstract 657].
83. 83. Coplan P, Nikas A, Saah A, et al. No association observed between indinavir therapy for HIV/AIDS and myocardial infarction in 4 clinical trials with 2,825 subjects. Sixth Conference on Retroviruses and Opportunistic Infections. Chicago, January 1999 [abstract 658].